A detailed history of Toth Financial Advisory Corp transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Toth Financial Advisory Corp holds 25 shares of HALO stock, worth $1,750. This represents 0.0% of its overall portfolio holdings.

Number of Shares
25
Holding current value
$1,750
% of portfolio
0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 09, 2025

BUY
$52.92 - $78.28 $1,323 - $1,957
25 New
25 $1,000
Q3 2024

Oct 21, 2024

BUY
$51.3 - $64.42 $51,300 - $64,420
1,000 New
1,000 $57,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $9.75B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Toth Financial Advisory Corp Portfolio

Follow Toth Financial Advisory Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Toth Financial Advisory Corp, based on Form 13F filings with the SEC.

News

Stay updated on Toth Financial Advisory Corp with notifications on news.